Active ingredient: Oseltamivir Phosphate

Form/Route: Capsule /Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover \textit{in-vivo}
   Strength: 75 mg
   Subjects: Healthy males and nonpregnant females, general population.
   Additional Comments:

2. Type of study: Fed
   Design: Single-dose, two-way crossover \textit{in-vivo}
   Strength: 75 mg
   Subjects: Healthy males and nonpregnant females, general population.
   Additional Comments:

Analytes to measure (in appropriate biological fluid): Oseltamivir and its metabolite, oseltamivir carboxylate in plasma.

Please submit the metabolite data as supportive evidence of comparable therapeutic outcome. For the metabolite, the following data should be submitted: individual and mean concentrations, individual and mean pharmacokinetic parameters, and geometric means and ratios of means for AUC and Cmax.

Bioequivalence based on (90\% CI): Oseltamivir

Waiver request of \textit{in-vivo} testing: 30 mg and 45 mg based on (i) acceptable bioequivalence studies on the 75 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a \textbf{Dissolution Methods Database} is available to the public at the OGD website at \url{http://www.accessdata.fda.gov/scripts/cder/dissolution/}. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Dec 2009